Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib

Oncoscience

Volumn 2, Issue 1, 2015, Pages 44-49

  Bailleux, Caroline ^a   Robert, Guillaume ^b,c   Ginet, Clémence ^b,c   Re, Daniel ^a   Thyss, Antoine ^a   Sudaka, Isabelle ^d   Peyrottes, Isabelle ^a   Hofman, Paul ^e   Auberger, Patrick ^b,c   Peyrade, Frederic ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSERM   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e PASTEUR HOSPITAL   (France)

Author keywords

Hairy cell leukemia; Re treatment; Relapse; V600E mutation; Vemurafenib

Indexed keywords

EID: 84941997000     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.111     Document Type: Article

References (7)

1. Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, Dalla Favera R and Pileri S. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004; 363(9424):1869-1870.
2. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364(24):2305-2315.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
4. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD and Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012; 366(21):2038-2040.
5. Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P and Robert G. Low-dose vemurafenib induces complete remission in a case of hairycell leukemia with a V600E mutation. Haematologica. 2013; 98(2):e20-22.
6. Dietrich S, Hullein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Frohling S, von Kalle C, Glimm H, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013; 31(19):e300-303.
7. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L and Rinderknecht JD. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014; 50(3):611-621.